October 5, 2017 / 2:10 PM / a year ago

U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent

Oct 5 (Reuters) - A U.S. appeals court has thrown out a ban on sales of Sanofi SA and Regeneron Pharmaceuticals Inc’s cholesterol-lowering drug Praluent, in a closely watched case that could have broad implications for drug development.

The ruling on Thursday from the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. is a setback for Amgen Inc, which claimed that the drug infringed its patents. (Reporting By Brendan Pierson in New York, Editing by Franklin Paul)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below